Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) on Tuesday announced a co-development agreement with AskHelpU, a Chinese patient association for amyotrophic lateral sclerosis (ALS).

This agreement aims to evaluate the efficacy of Biophytis' lead drug candidate, BIO101, in treating ALS.

The collaboration combines Biophytis' drug development expertise with AskHelpU's deep understanding of ALS.

Preclinical studies will be conducted in China, leveraging the expertise of leading Chinese universities and research laboratories. If preclinical results are positive, the development programme may progress to larger-scale clinical trials.